Wet Age-related Macular Degeneration
Showing 1 - 25 of 44
Wet Age-related Macular Degeneration Trial in Beijing (RC28-E, Aflibercept)
Recruiting
- Wet Age-related Macular Degeneration
-
Beijing, Beijing, ChinaBeijing Hospital
Feb 3, 2023
Data of Intravitreal Aflibercept Injection in Patients of Wet
Completed
- Wet Age-related Macular Degeneration
- Aflibercept (Eylea, BAY86-5321)
-
Multiple Locations, IndiaMany Locations
Feb 2, 2023
s in Wet Age-related Macular Degeneration Which Have Never
Active, not recruiting
- Wet Age-related Macular Degeneration
- Aflibercept (Eylea, BAY86-5321)
-
Multiple Locations, Argentina
- +16 more
Jan 16, 2023
Wet Age-related Macular Degeneration, Retinal Vein Occlusion, Diabetic Macular Edema Trial in United States (KSI-301)
Terminated
- Wet Age-related Macular Degeneration
- +2 more
-
Phoenix, Arizona
- +10 more
Nov 1, 2022
Wet Age-related Macular Degeneration Trial in United States (Eyp-1901, Aflibercept 2Mg/0.05Ml Inj,Oph)
Recruiting
- Wet Age-related Macular Degeneration
- Eyp-1901
- Aflibercept 2Mg/0.05Ml Inj,Oph
-
Melbourne, Florida
- +4 more
Aug 18, 2022
Wet Age-related Macular Degeneration Trial (Ranibizumab, SCT510A)
Not yet recruiting
- Wet Age-related Macular Degeneration
- (no location specified)
Jul 28, 2022
AMD, nAMD, Wet Age-related Macular Degeneration Trial in United States (RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept (EYLEA®))
Recruiting
- AMD
- +5 more
- RGX-314 Dose 1
- +2 more
-
Encino, California
- +16 more
Jun 2, 2022
Wet Age-related Macular Degeneration Trial in Puerto Rico, United States (KSI-301, Aflibercept, Sham Procedure)
Active, not recruiting
- Wet Age-related Macular Degeneration
- KSI-301
- +2 more
-
Phoenix, Arizona
- +65 more
Jun 2, 2022
Wet Age-related Macular Degeneration Trial in Boston, Worcester (Intravitreal anti-VEGF, Intravitreal AAVCAGsCD59, Oral
Completed
- Wet Age-related Macular Degeneration
- Intravitreal anti-VEGF
- +2 more
-
Boston, Massachusetts
- +1 more
May 24, 2022
Wet Age-related Macular Degeneration Trial in Bern (Aflibercept, Brolucizumab, early treat and extend (T&E))
Enrolling by invitation
- Wet Age-related Macular Degeneration
- Aflibercept
- +2 more
-
Bern, SwitzerlandBerner Augenklinik am Lindenhofspital
May 13, 2022
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration Trial in Worldwide (SCD411, Aflibercept)
Active, not recruiting
- Wet Age-related Macular Degeneration
- Neovascular Age-related Macular Degeneration
-
Beverly Hills, California
- +139 more
May 11, 2022
Wet Age-related Macular Degeneration Trial in Beijing (Aflibercept)
Completed
- Wet Age-related Macular Degeneration
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Apr 19, 2022
Wet Age-related Macular Degeneration Trial (SCB-420, Aflibercept)
Withdrawn
- Wet Age-related Macular Degeneration
- (no location specified)
Apr 12, 2022
Exudative Macular Degeneration, Wet Age-related Macular Degeneration Trial in Iowa City (Doxycycline Hyclate, Placebo)
Recruiting
- Exudative Macular Degeneration
- Wet Age-related Macular Degeneration
- Doxycycline Hyclate
- Placebo
-
Iowa City, IowaUniversity of Iowa Hospitals & Clinics Department of Ophthalmolo
Apr 5, 2022
Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration Trial in United States (ADVM-022)
Active, not recruiting
- Wet Age-related Macular Degeneration
- Neovascular Age-related Macular Degeneration
- ADVM-022
-
Bakersfield, California
- +10 more
Mar 21, 2022
s in Wet AMD in Active Smokers
Completed
- Wet Age-related Macular Degeneration
- Medical Data extraction
-
Brussels, BelgiumCHU Brugmann
Mar 7, 2022
Wet Age-related Macular Degeneration Trial in Hungary, Latvia, United States (Zimura, Lucentis)
Completed
- Wet Age-related Macular Degeneration
-
Phoenix, Arizona
- +27 more
Feb 3, 2022
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
Enrolling by invitation
- Wet Age-related Macular Degeneration
- Neovascular Age-related Macular Degeneration
- ADVM-022
-
Bakersfield, California
- +8 more
Dec 23, 2021
Wet Age-related Macular Degeneration Trial in China (2.5mg of BAT5906, 4mg of BAT5906)
Completed
- Wet Age-related Macular Degeneration
- 2.5mg of BAT5906
- 4mg of BAT5906
-
Beijing, Beijing, China
- +15 more
Nov 30, 2021
Healthy Volunteers, Wet Age-related Macular Degeneration Trial in Fukuoka (Placebo, KHK4951)
Recruiting
- Healthy Volunteers
- Wet Age-related Macular Degeneration
- Placebo
- KHK4951
-
Fukuoka, JapanHakata clinic
Nov 10, 2021
Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, Wet Age-related Macular Degeneration Trial in United
Recruiting
- Neovascular Age-related Macular Degeneration
- +2 more
- RGX-314
-
Phoenix, Arizona
- +12 more
Oct 12, 2021
Neovascular Age-related Macular Degeneration, Wet Age-related Macular Degeneration Trial in United States (RGX-314)
Active, not recruiting
- Neovascular Age-related Macular Degeneration
- Wet Age-related Macular Degeneration
- RGX-314
-
Santa Barbara, California
- +7 more
Apr 1, 2021